Adrenergic Uptake Inhibitors
"Adrenergic Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.
| Descriptor ID |
D018759
|
| MeSH Number(s) |
D27.505.519.562.437.050 D27.505.519.625.050.601 D27.505.519.625.600.050 D27.505.696.577.050.601 D27.505.696.577.600.050
|
| Concept/Terms |
Adrenergic Uptake Inhibitors- Adrenergic Uptake Inhibitors
- Inhibitors, Adrenergic Reuptake
- Reuptake Inhibitors, Adrenergic
- Uptake Inhibitors, Adrenergic
- Adrenergic Reuptake Inhibitors
- Inhibitors, Adrenergic Uptake
|
Below are MeSH descriptors whose meaning is more general than "Adrenergic Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Adrenergic Uptake Inhibitors".
This graph shows the total number of publications written about "Adrenergic Uptake Inhibitors" by people in this website by year, and whether "Adrenergic Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 2 | 0 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 4 | 2 | 6 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adrenergic Uptake Inhibitors" by people in Profiles.
-
Real-World Experiences with VMAT2 Inhibitors in Pediatric Hyperkinetic Movement Disorders. Tremor Other Hyperkinet Mov (N Y). 2025; 15:26.
-
Acute vagus nerve stimulation enhances reversal learning in rats. Neurobiol Learn Mem. 2021 10; 184:107498.
-
Deutetrabenazine for the treatment of Huntington's chorea. Expert Rev Neurother. 2018 08; 18(8):625-631.
-
Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea. JAMA Neurol. 2017 08 01; 74(8):977-982.
-
Care Provision and Prescribing Practices of Physicians Treating Children and Adolescents With ADHD. Psychiatr Serv. 2017 Jul 01; 68(7):681-688.
-
Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. JAMA. 2016 Jul 05; 316(1):40-50.
-
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011 Nov; 11(11):1509-23.
-
Dramatic response of facial stereotype/tic to tetrabenazine in the first reported cases of neuroferritinopathy in the United States. Mov Disord. 2010 Oct 30; 25(14):2470-2.
-
Treatment of hyperkinetic movement disorders. Lancet Neurol. 2009 Sep; 8(9):844-56.
-
Atomoxetine for freezing of gait in Parkinson disease. J Neurol Sci. 2009 Sep 15; 284(1-2):177-8.